Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial

Eiji Oki, Akitaka Makiyama, Yuji Miyamoto, Masahito Kotaka, Hirofumi Kawanaka, Keisuke Miwa, Akira Kabashima, Tomohiro Noguchi, Kotaro Yuge, Tomomi Kashiwada, Koji Ando, Mototsugu Shimokawa, Hiroshi Saeki, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara, Masaki Mori

Open source

DOI: 10.1002/cam4.3618
Published: 2020-11-29
Container: Cancer Medicine
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cam4.3618,
  title = {Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial},
  author = {Eiji Oki and Akitaka Makiyama and Yuji Miyamoto and Masahito Kotaka and Hirofumi Kawanaka and Keisuke Miwa and Akira Kabashima and Tomohiro Noguchi and Kotaro Yuge and Tomomi Kashiwada and Koji Ando and Mototsugu Shimokawa and Hiroshi Saeki and Yoshito Akagi and Hideo Baba and Yoshihiko Maehara and Masaki Mori},
  year = {2020},
  journal = {Cancer Medicine},
  doi = {10.1002/cam4.3618},
  url = {https://doi.org/10.1002/cam4.3618}
}

RIS

TY  - JOUR
TI  - Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
AU  - Eiji Oki
AU  - Akitaka Makiyama
AU  - Yuji Miyamoto
AU  - Masahito Kotaka
AU  - Hirofumi Kawanaka
AU  - Keisuke Miwa
AU  - Akira Kabashima
AU  - Tomohiro Noguchi
AU  - Kotaro Yuge
AU  - Tomomi Kashiwada
AU  - Koji Ando
AU  - Mototsugu Shimokawa
AU  - Hiroshi Saeki
AU  - Yoshito Akagi
AU  - Hideo Baba
AU  - Yoshihiko Maehara
AU  - Masaki Mori
PY  - 2020
JO  - Cancer Medicine
DO  - 10.1002/cam4.3618
UR  - https://doi.org/10.1002/cam4.3618
ER  -

APA

Oki, E., Makiyama, A., Miyamoto, Y., Kotaka, M., Kawanaka, H., Miwa, K., Kabashima, A., Noguchi, T., Yuge, K., Kashiwada, T., Ando, K., Shimokawa, M., Saeki, H., Akagi, Y., Baba, H., Maehara, Y., & Mori, M. (2020). Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial. Cancer Medicine. https://doi.org/10.1002/cam4.3618

Source records

crossref · retrieved 2026-09-25T10:36:12.527Z